A Phase 2 interventional study of CC-11050 in Erythema Nodosum Leprosum and Leprosy, sponsored by The Leprosy Mission Nepal. Status unknown at 2 sites in Nepal. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-07.
Sponsored by The Leprosy Mission Nepal · Phase 2, Interventional, and Treatment
This study will be a single center, Phase 2, open-label trial to evaluate the safety and efficacy of 200mg CC-11050 administered twice daily taken with food for patients with moderate to severe ENL. The study will be performed in two steps: 1) to evaluate immediate effect in safety and efficacy of drug in 10 males with new or new recurrent episode ENL and, if found to be safe and effective by the DSMB and 2) if allowed by the DSMB, and approved by relevant study stakeholders, an additional 40 ENL patients will be enrolled for up to 52 weeks of treatment. A safety analysis will be conducted on all patients who have received at least one dose of study drug, and will include the frequency of all adverse events and laboratory abnormalities as well as frequency of dose interruptions, dose reductions and treatment discontinuation.
Study participants must satisfy the following criteria to be enrolled in the study:
Exclusion Criteria:
The presence of any of the following will exclude a participant from enrollment:
200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
Drug: CC-11050
CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
Number of participants with moderate to severe ENL with severity changes as assessed by the ENL Severity Scale.
Changes in ENL Severity Scale Score (Walker et al., PLoS Negl Trop Dis 11(7): e0005716, https://doi.org/10.1371/journal.pntd.0005716) as compared to baseline and any previous time points. Ten clinical categories contribute 0-3 points toward the total score of 0-30. An ENL patient with a total scale score of less than 9 is considered to have mild ENL, while scores \>9 are considered moderate to severe ENL. A minimum score of 9 is required to indicate sufficient ENL symptoms from which post-intervention reduction in score(s) can be determined meaningful improvement.
Time frame: 10 days, 28 days and monthly up to 1 year of treatment
Number of participants with moderate to severe ENL with decreased duration of episode(s) as assessed by standard ENL episode definition.
Changes in ENL episode duration(s) as compared to baseline and any previous time points. By definition, if ENL symptoms are separated by time and no need of treatment for \>28 days, they are considered separate episodes. Recurrence is anytime another episode occurs after \>28 days of no prior treatment or symptoms.
Time frame: 10 days, 28 days, monthly up to 1 year of treatment and up to 1 year followup after treatment cessation.
Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed by slit skin smear microscopy.
Changes in slit skin smear microscopy BI as compared to baseline. BI can range from 0-6.
Time frame: Enrolment and after 1 year treatment.
Number of participants with moderate to severe ENL with decreased bacterial index (BI) as assessed skin histopathology.
Changes in skin histopathology bacterial index (BI) as compared to baseline. BI can range from 0-6.
Time frame: Enrolment and after 1 year treatment.
Number of patients with moderate to severe ENL with improved peripheral neuropathy as assessed by standardized monofilament and voluntary muscle tests.
Changes in scores for peripheral neuropathy as indicated by monofilament and voluntary muscle tests compared from baseline and any previous time points. To check neuropathy, 7 motor function nerves and 6 sensory function nerves on each side of the body are assessed for a total 26 nerves. Each are assessed on 3 sites using a standard set of Semmes-Weinstein monofilaments. The 200mg filament and the 2g filament represent threshold for the hand and foot, respectively. The 0-5 Medical Research Council (MRC) scale is used for motor function assessment. Sensory scores \>3 and motor nerve scoring (MRC) \< 5 are regarded impaired (indicating neuropathy). More method specifics can be found here: van Veen N.H., et al., Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev, 2007(2): p. CD005491.
Time frame: enrolment, 10 days, 28 days, biweekly (as needed), up to 1 year treatment, up to 1 year followup after treatment cessation
Number of participants with moderate to severe ENL with improved quality of life as assessed by the World Health Organization Quality of Life tool.
Changes in scores for the World Health Organization Quality of Life assessment as compared to baseline and any previous time points. There are 26 questions in this questionnaire and each can be scored from 1 to 5 points. The highest possible score is 130 and lowest possible score is 26. A higher score denotes better quality of life.
Time frame: Enrolment, 28 days, monthly up to 1 year of treatment and up to 1 year followup after treatment cessation.
Number of participants with moderate to severe ENL as assessed by standard blood panel and basic metabolic testing.
Abnormalities or change in values in comparison to baseline and any previous time points.
Time frame: Enrolment, day 10, day 17, day 28, monthly up to 1 year of treatment, and 1 month post-cessation of treatment.
Number of participants with moderate to severe ENL as assessed by urinalysis.
Detection of albumin (qualitative) as compared to baseline and any previous time points. Urine albumin is related to ENL severity and kidney function test.
Time frame: Enrolment, day 10, day 17, day 28, monthly up to 1 year of treatment, and 1 month post-cessation of treatment.
Number of participants with moderate to severe ENL as assessed by serological indicators associated with ENL.
Detection of rheumatoid arthritis factor (positive) and/or C-reactive protein (positive) as compared to baseline and any previous time points.
Time frame: Enrolment, day 10, day 17, day 28, monthly up to 1 year of treatment, and 1 month post-cessation of treatment.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.